Breaking News Headlines Today | Ground News

See every side of every news story

healtheconomics.com image

News from healtheconomics.com

All of today’s top news stories from healtheconomics.com. Get the full analysis behind how media bias impacts breaking news.

We’ve discovered 58 headlines written by healtheconomics.com during the past 3 months.

healtheconomics.com’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

healtheconomics.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about healtheconomics.com

Where is healtheconomics.com located?healtheconomics.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top healtheconomics.com News

Merck spends $10 billion for Verona, gaining access to its COPD medication

Merck · United States

Merck spends $10 billion for Verona, gaining access to its COPD medication

66% Center coverage: 48 sources

AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline

AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline

87% Center coverage: 8 sources

AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells. The University of Pennsylvania spinout’s lead program recently began a Phase 1 test as a potential treatment for B cell-mediated autoimmune disorders. The post AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline appeared first on MedCity News.See the Story

Intuitive’s Da Vinci 5 Surgical System Receives CE Mark

Intuitive’s Da Vinci 5 Surgical System Receives CE Mark

60% Center coverage: 5 sources

Fifth-generation da Vinci surgical system approved for use in Europe across multiple procedures...See the Story

Trump Administration Warns Maryland to Drop ‘Gender Ideology’ From Federally Funded Programs

100% Center coverage: 2 sources

Federal health officials warn Maryland they may lose millions in funding if sex-ed programs don’t drop gender identity and LGBT topics.LGBTQ+ · United States See the Story

BlueRock Initiates First Human Trial of iPSC Cell Therapy for Retinal Diseases

BlueRock Therapeutics, a Bayer subsidiary, has launched the CLARICO trial, marking the first clinical study of an induced pluripotent stem cell (iPSC)-derived therapy for primary photoreceptor diseases, such as retinitis pigmentosa and cone-rod dystrophy. The Phase I/II trial will assess the safety, tolerability, and efficacy of OpCT-001 in approximately 54 adults, focusing initially on safety through a dose-escalation design before evaluating v…Read Article

The American Way to Lower Drug Prices

100% Right coverage: 1 sources

President Trump is attempting to reshape America’s biotech industry with two primary objectives. He wants more medicines to be made in the United States. And he wants to ensure American patients get the lowest prices in the world.Donald Trump · United States See the Story

First German Patient Receives HEMGENIX Gene Therapy for Haemophilia B

In a groundbreaking development, the first haemophilia B patient in Germany has been treated with the one-time gene therapy HEMGENIX at Hannover Medical School. Developed by CSL Behring, HEMGENIX is the first gene therapy of its kind approved in Europe for adults with severe forms of the disorder and represents a significant advancement in addressing the genetic cause of haemophilia B. Christian Schepperle of Interessengemeinschaft Hämophiler e.…Lower Saxony · Lower Saxony Read Article

CVS Benefits Arm Slapped With $95M In Medicare Overbilling Judgment — Penalty Could Triple By Stocktwits

65% Center coverage: 14 sources

PHILADELPHIA, June 27, 2025 /PRNewswire/ -- Berger Montague PC and Miller Shah LLP, on behalf of their whistleblower client, are pleased to announce that on June 25, 2025, a Pennsylvania federal judge found pharmacy benefits manager Caremark and related entities…Trees · Philadelphia See the Story

UCSF to Lay Off About 200 Employees Amid ‘Serious Financial Challenges’

67% Center coverage: 3 sources

(KRON) -- Approximately 200 University of California, San Francisco (UCSF) healthcare employees are being laid off, the university announced in a press release Wednesday. UCSF called it a difficult but necessary decision to combat "serious financial challenges" the hospital is facing. "We are deeply grateful for their contributions. Impacted employees will receive full UC benefits, including severance and support with career transition," UCSF sa…Unions · San Francisco See the Story

CMS to Finalize Drug Price Transparency Rule in 2025, Aiming to Lower Costs and Increase Accountability

On June 24, U.S. Surgeon General Mehmet Oz announced that the Centers for Medicare & Medicaid Services (CMS) will finalize a rule this year requiring insurers to publicly report the net prices paid for prescription drugs. Originally proposed under the Trump administration and withdrawn in 2022, the rule has been revived as part of the Biden administration’s drug pricing reform efforts. If finalized, the rule would mandate both public and private…Mehmet Oz · United States See the Story

Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment

Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its late stage at diagnosis and its resistance to chemotherapy…NHS · England See the Story

Breaking News Topics Related to healtheconomics.com